ArticleAntimicrobial agents and chemotherapy2004
Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Novel Betulinic Acid-Nucleoside Hybrids with Potent Anti-HIV Activity.ACS medicinal chemistry letters · 2020Article
- Structure and Anti-HIV Activity of Betulinic Acid Analogues.Current medical science · 2018Review
- Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives.Medicinal research reviews · 2018Review
- Structure Optimization of Aloperine Derivatives as HIV-1 Entry Inhibitors.ACS medicinal chemistry letters · 2017Article
- Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.ACS medicinal chemistry letters · 2016Article
- Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.Bioorganic & medicinal chemistry letters · 2012Article
- New betulinic acid derivatives as potent proteasome inhibitors.Bioorganic & medicinal chemistry letters · 2011Article
- Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.Journal of medicinal chemistry · 2009Article
- New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.Antimicrobial agents and chemotherapy · 2009Article
- Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.Journal of medicinal chemistry · 2009Article
- Proteasome regulators: activators and inhibitors.Current medicinal chemistry · 2009Review
- Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.Journal of medicinal chemistry · 2008Article
- Activation and inhibition of the proteasome by betulinic acid and its derivatives.FEBS letters · 2007Article
- Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.Journal of medicinal chemistry · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A class of betulinic acid derivatives was synthesized to target two critical steps in the human immunodeficiency virus type 1 (HIV-1) replication cycle, entry and maturation. Each mechanism of HIV-1 inhibition is distinct from clinically available anti-HIV therapeutics. The viral determinants of the antientry and antimaturation activities are the bridging sheet of HIV-1 gp120 and the P24/p2 cleavage site, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.